Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.16), $0.13 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $13.33 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.